Johnson Electric (China)

Recent papers from Johnson Electric (China)

1. Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUSJournal of Clinical Oncology · 2026
2. Correlation between tissue temperature and ablation interval time under ultra-high-power short-duration ablation: Ex vivo porcine modelJournal of Interventional Cardiac Electrophysiology · 2026
3. Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyJournal of Clinical Oncology · 2026
4. Two decades of landscape change in the treatment of multiple myeloma.Journal of Clinical Oncology · 2026
5. Development and external validation of a computational approach for accelerated read out of randomized clinical trials in metastatic prostate cancer.Journal of Clinical Oncology · 2026
6. Overall survival of first-line amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.Journal of Clinical Oncology · 2026
7. Antitumor activity of amivantamab by consensus molecular subtypes in RAS / BRAF wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b/2 OrigAMI-1 study.Journal of Clinical Oncology · 2026
8. Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trialsIntestinal Research · 2026
9. Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE StudiesClinical Lymphoma Myeloma & Leukemia · 2026
10. Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE StudyInternational Journal of Urology · 2026
11. Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II StudyJournal of Clinical Oncology · 2026
12. Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 studyAnnals of Hematology · 2026
13. Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: a randomized trialInfection · 2026
14. Phase 1 safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of pasritamig in Asian population with metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2026
15. Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI studyIntestinal Research · 2026
16. Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisLung Cancer · 2026
17. Amivantamab plus FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b/2 OrigAMI-1 study.Journal of Clinical Oncology · 2026
18. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology · 2026
19. Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4Blood Cancer Journal · 2025
20. A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ‐63733657) in Healthy Chinese AdultsThe Journal of Clinical Pharmacology · 2025